摘要
目的分析维格列汀、格列美脲分别联合二甲双胍治疗2型糖尿病(T2MD)的效果及对血糖波动、体重的影响。方法选取本院2018年1~11月收治的684例T2MD患者,按照不同治疗方案将其纳入维格列汀组(85例)与格列美脲组(599例),分别给予维格列汀联合二甲双胍治疗与格列美脲联合二甲双胍治疗,比较两组的治疗效果、血糖指标(空腹血糖、餐后2h血糖、糖化血红蛋白)、动态血糖监测情况(血糖达标时间、24h平均血糖、血糖波动幅度)以及体重变化(BMI体重指数)。结果维格列汀组的总有效率(94.1%)高于格列美脲组(87.5%),维格列汀组用药后的血糖指标优于格列美脲组,维格列汀组的动态血糖监测情况优于格列美脲组,维格列汀组患者用药后的体重指数小于格列美脲组,差异均有统计学意义(P<0.05)。结论维格列汀联合二甲双胍治疗T2MD的效果优于格列美脲联合二甲双胍治疗,可有效控制血糖,且可减小血糖波动幅度,减轻患者体重,值得推行。
Objective To analyze curative effects of vildagliptin and glimepiride combined with metformin in treatment of type 2 diabetes mellitus(T2MD) and its effect on blood glucose fluctuation and body weight. Methods 684 T2MD patients who were treated in our hospital from January to November 2018 were selected.According to different treatment regimens,they were divided into the vildagliptin group(85 cases) and the glimepiride group(599 cases).The vildagliptin was treated with vildagliptin combined with metformin while the glimepiride group was treated with glimepiride combined with metformin.The curative effects,blood glucose levels (fasting blood glucose,postprandial 2h blood glucose,glycated hemoglobin),dynamic blood glucose monitoring(time of reaching target of glucose,24h mean blood glucose,blood glucose fluctuation)and body weight change(BMI body mass index)were compared between the two groups. Results The total effective rate of the vildagliptin group(94.1%)was higher than that of the glimepiride group(87.5%).After medication,the blood glucose level of the vildagliptin group was better than that of the glimepiride group.The dynamic blood glucose monitoring of the vildagliptin group was better than that of the glimepiride group. Patients in the vildagliptin group had a lower body mass index than the glimepiride group.The differences were statistically significant(P < 0.05). Conclusion The curative effect of vildagliptin combined with metformin in the treatment of T2MD is superior to glimepiride combined with metformin.It can effectively control blood glucose,reduce the blood glucose fluctuation and reduce the weight of patients,which is worth promoting.
作者
薛颖妍
夏曦
XUE Yingyan;XIA Xi(The Third Affiliated Hospital of Guangdong Medical University(Longjiang Hospital of Shunde District,FoshanCity),Guangdong,Foshan 528318,China)
出处
《中国医药科学》
2019年第13期39-41,共3页
China Medicine And Pharmacy
